NO20052860L - Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme - Google Patents

Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme

Info

Publication number
NO20052860L
NO20052860L NO20052860A NO20052860A NO20052860L NO 20052860 L NO20052860 L NO 20052860L NO 20052860 A NO20052860 A NO 20052860A NO 20052860 A NO20052860 A NO 20052860A NO 20052860 L NO20052860 L NO 20052860L
Authority
NO
Norway
Prior art keywords
pellet
acrylic polymer
water
cores
tamsulosin
Prior art date
Application number
NO20052860A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052860D0 (no
Inventor
Johannes Jan Platteeuw
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23131212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052860(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of NO20052860D0 publication Critical patent/NO20052860D0/no
Publication of NO20052860L publication Critical patent/NO20052860L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20052860A 2002-11-14 2005-06-13 Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme NO20052860L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/293,940 US7018658B2 (en) 2002-11-14 2002-11-14 Pharmaceutical pellets comprising tamsulosin
PCT/NL2002/000821 WO2004043449A1 (en) 2002-11-14 2002-12-12 Pharmaceutical pellets comprising tamsulosin and a process for making the same

Publications (2)

Publication Number Publication Date
NO20052860D0 NO20052860D0 (no) 2005-06-13
NO20052860L true NO20052860L (no) 2005-08-10

Family

ID=23131212

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052860A NO20052860L (no) 2002-11-14 2005-06-13 Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme

Country Status (23)

Country Link
US (1) US7018658B2 (pl)
EP (1) EP1562573B1 (pl)
JP (1) JP5405710B2 (pl)
AT (2) ATE323478T1 (pl)
AU (3) AU2002351451A1 (pl)
BE (1) BE1015435A4 (pl)
CA (1) CA2415840C (pl)
CH (1) CH696419A5 (pl)
CZ (1) CZ13341U1 (pl)
DE (2) DE60210828T2 (pl)
DK (2) DK1562573T3 (pl)
ES (1) ES2257589T3 (pl)
FI (1) FI5842U1 (pl)
FR (1) FR2847166B1 (pl)
GB (1) GB2395125B (pl)
HU (1) HUP0500832A3 (pl)
NL (1) NL1022151C2 (pl)
NO (1) NO20052860L (pl)
PL (1) PL206083B1 (pl)
PT (1) PT1562573E (pl)
SI (1) SI21394A2 (pl)
WO (2) WO2004043449A1 (pl)
ZA (1) ZA200503696B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003211146B2 (en) * 2002-02-21 2007-07-19 Valeant International (Barbados) Srl Controlled release dosage forms
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
EA200600066A1 (ru) * 2003-07-01 2006-06-30 Крка, Товарна Здравил, Д.Д. Ново Место Тамсулозинсодержащее ядро, покрытое поливинилпирролидоном или поливинилацетатом
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
WO2005053659A1 (en) * 2003-12-03 2005-06-16 Natco Pharma Limited An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
KR100615952B1 (ko) * 2004-05-27 2006-08-28 한국화학연구원 서방형 약물 전달 시스템
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
ATE363894T1 (de) * 2004-07-14 2007-06-15 Siegfried Generics Int Ag Granulat zur kontrollierten freisetzung von tamsulosin, enthaltend alginat
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007017253A1 (de) * 2005-08-10 2007-02-15 Add Advanced Drug Delivery Technologies Ltd. Orales präparat mit kontrollierter freisetzung eines benzolsulfonamids
KR20070021806A (ko) * 2005-08-19 2007-02-23 (주)아모레퍼시픽 α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법
KR100745515B1 (ko) * 2006-04-10 2007-08-02 주식회사 대웅제약 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법
WO2007131804A1 (en) * 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
SI2217228T1 (sl) * 2007-10-12 2012-07-31 KRKA@@tovarna@zdravil@@d@d@@Novo@mesto Trdni farmacevtski sestavek ki obsega tamsulozin
EP2047847A1 (en) * 2007-10-12 2009-04-15 KRKA, tovarna zdravil, d.d., Novo mesto Solid pharmaceutical composition comprising tamsulosin
EP2373297A1 (en) * 2008-12-09 2011-10-12 Synthon B.V. Tamsulosin pellets for fixed dose combination
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
WO2013123965A1 (en) 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
LT2838512T (lt) 2012-04-18 2018-11-12 Grünenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
RU2015143891A (ru) 2013-06-21 2017-07-24 Вокхардт Лимитед Фармацевтические составы тамсулозина или его солей
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
CZ2015225A3 (cs) * 2015-03-30 2016-10-12 Zentiva, K.S. Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
CN105287395A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种盐酸坦索罗辛缓释微丸及其制备方法
US20190125685A1 (en) 2016-03-31 2019-05-02 Hanmi Pharm. Co., Ltd. Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate
EP3473244A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
EP3473245A1 (en) 2017-10-20 2019-04-24 Veru Inc. Controlled release oral tamsulosin hydrochloride
PT4422599T (pt) 2021-10-25 2026-04-16 Farmalider Sa Suspensão oral de tadalafil

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
JPS61100526A (ja) * 1984-10-22 1986-05-19 Kyowa Hakko Kogyo Co Ltd 持続性ドパミン経黒剤
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
JPH07316077A (ja) * 1994-05-20 1995-12-05 Sumitomo Pharmaceut Co Ltd 腸溶性コーティング用組成物
US6177430B1 (en) * 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
BR0009327A (pt) * 1999-08-09 2002-01-22 Yamanouchi Pharma Co Ltd Composição farmacêutica para a terapia de sintomas do trato urinário inferior
JP3154710B1 (ja) * 1999-08-09 2001-04-09 山之内製薬株式会社 下部尿路症治療剤
BR0013720A (pt) * 1999-09-02 2002-07-23 Nostrum Pharmaceuticals Inc Formulação em pelota de liberação controlada
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
WO2003039530A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin

Also Published As

Publication number Publication date
HUP0500832A3 (en) 2009-12-28
US7018658B2 (en) 2006-03-28
HUP0500832A2 (en) 2007-07-30
FR2847166A1 (fr) 2004-05-21
AU2003288083A1 (en) 2004-06-03
BE1015435A4 (nl) 2005-04-05
NO20052860D0 (no) 2005-06-13
DK200300005U3 (da) 2003-04-25
GB0229021D0 (en) 2003-01-15
ATE323478T1 (de) 2006-05-15
FI5842U1 (fi) 2003-07-03
PL206083B1 (pl) 2010-06-30
AU2003200059B2 (en) 2008-07-03
GB2395125A (en) 2004-05-19
DE60210828D1 (de) 2006-05-24
CA2415840C (en) 2008-11-18
FR2847166B1 (fr) 2005-06-10
AU2002351451A1 (en) 2004-06-03
DK1562573T3 (da) 2006-08-21
DE60210828T2 (de) 2006-10-19
JP2006508960A (ja) 2006-03-16
PT1562573E (pt) 2006-07-31
ES2257589T3 (es) 2006-08-01
CA2415840A1 (en) 2004-05-14
CZ13341U1 (cs) 2003-06-02
DE20219293U1 (de) 2003-06-05
CH696419A5 (de) 2007-06-15
SI21394A2 (sl) 2004-06-30
WO2004043448A1 (en) 2004-05-27
PL357856A1 (pl) 2004-05-17
WO2004043449A1 (en) 2004-05-27
US20040096502A1 (en) 2004-05-20
JP5405710B2 (ja) 2014-02-05
EP1562573A1 (en) 2005-08-17
AT6542U1 (de) 2003-12-29
NL1022151C2 (nl) 2004-05-18
EP1562573B1 (en) 2006-04-19
AU2003200059A1 (en) 2004-06-03
GB2395125B (en) 2007-06-06
ZA200503696B (en) 2006-08-30
FIU20020500U0 (fi) 2002-12-16

Similar Documents

Publication Publication Date Title
CA2415840A1 (en) Pharmaceutical pellets comprising tamsulosin and a process for making the same
RU2127587C1 (ru) Устойчивые лекарственные формы с регулируемым выделением, имеющие акриловые полимерные покрытия, (варианты) и способ их получения
ATE380022T1 (de) Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
CN100490790C (zh) 一种奥美拉唑肠溶微丸胶囊及其制备方法
WO2004022031A3 (en) Stable probiotic microsphere compositions and their methods of preparation
CA2382098C (en) Sustained-release, oral pharmaceutical forms of administration
AU593259B2 (en) Solid, stable dosage forms with an elastic film coating
US4367217A (en) Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof
CA1205384A (en) Delayed-release form of bromhexine and process for the preparation thereof
BG105061A (bg) Ентерично покрит фармацевтичен състав и метод за получаване
US5175003A (en) Dual mechanism controlled release system for drug dosage forms
CA2611114A1 (en) An entacapone-containing oral dosage form
CA2383220A1 (en) Controlled release pellet formulation
WO2015193788A1 (en) Formulation for oral administration containing mesalazine
YU57692A (sh) Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
NO792335L (no) Legemiddel-retardform med uopploeselige, poroese diffusjonsovertrekk
US6117450A (en) Method of making a perorally administered solid drug with controlled effective ingredient delivery
BG101901A (bg) 2-метил-тиено-бензодиазепинова формулировка за приемане през устата и метод за нейното получаване
JP2007507553A5 (pl)
DE69622510D1 (de) Nifedipinzubereitung mit langanhaltender Freisetzung
ATE243026T1 (de) Bupropion-darreichungsform mit kontrollierter freisetzung
RU2013125148A (ru) Пероральная фармацевтическая таблетка с регулируемым высвобождением месалазина и способ ее получения
WO2009090484A3 (en) Mesalazine tablet
JP2008507483A (ja) 安定な作用物質放出プロフィールを有するコーティングされた剤形の製造方法
SU1218919A3 (ru) Способ получени цефалексина продленного действи дл перорального применени

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application